INTRODUCTION {#s1}
============

Gastric cancer is the fifth most common malignancy, and the third leading cause of cancer-related death worldwide \[[@R1]\], although incidences have declined in recent decades. Surgical therapy remains the optimal treatment for non-metastatic gastric cancer. Still, even with advances in surgical techniques and adjuvant therapy options, advanced gastric cancer patient prognoses are poor \[[@R2]\].

Surgeons commonly encounter patients with impaired pulmonary function during preoperative evaluation. Pulmonary comorbidity increases the risk of postoperative respiratory complications \[[@R3]\]. Thus, preoperative evaluation of pulmonary function is widely used to select surgical candidates and predict the occurrence of postoperative respiratory complications, especially in the field of thoracic surgery \[[@R4]\]. Recent studies also investigated the influence of pulmonary function on abdominal surgery outcomes \[[@R5], [@R6]\]. However, the prognostic value of preoperative pulmonary function in gastric cancer patients has not yet been investigated. The present study assessed the value of pulmonary function in predicting gastric cancer patient prognosis and the likelihood of postoperative complications.

RESULTS {#s2}
=======

Our study included 949 male (78.4%) and 261 female (21.6%) gastric cancer patients (Table [1](#T1){ref-type="table"}). Median patient age was 59 years (range: 20--87), and median follow-up time was 25 months (range: 1--75). Patient 1-, 3- and 5-year overall survival rates were 88.8%, 65.7% and 53.0%, respectively (Figure [1](#F1){ref-type="fig"}).

###### Clinicopathological characteristics of gastric cancer patients

  Characteristics                 Number (n=1210)   Percent
  ------------------------------- ----------------- ---------
  Gender                                            
   Male                           949               78.4
   Female                         261               21.6
  Age                                               
   ≤60                            701               38.0
   \>60                           509               62.0
  BMI                                               
   \<18.5                         107               8.9
   ≥18.5-\<25.0                   862               71.2
   ≥25.0                          241               19.9
  Total protein                                     
   \<65.0                         338               27.9
   ≥65.0                          872               72.1
  Albumin                                           
   \<40.0                         264               21.8
   ≥40.0                          946               78.2
  Tumor location                                    
   Upper third                    425               35.1
   Middle third                   201               16.6
   Lower third                    502               41.5
   Entire                         82                6.8
  Tumor size (cm)                                   
   ≤5                             810               66.9
   \>5                            400               33.1
  Borrmann type                                     
   I                              155               15.7
   II                             320               32.3
   III                            426               43.1
   IV                             88                8.9
  Pathological type                                 
   Well differentiated            104               8.6
   Moderately differentiated      308               25.5
   Poorly differentiated          754               62.3
   Signet ring cell or Mucinous   44                3.6
  Tumor depth                                       
   T1                             223               18.4
   T2                             111               9.2
   T3                             433               35.8
   T4                             443               36.6
  Lymph node metastasis                             
   N0                             413               34.1
   N1                             210               17.4
   N2                             206               17.0
   N3                             381               31.5
  Tumor stage                                       
   I                              265               21.9
   II                             330               27.3
   III                            615               50.8
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Forced vital capacity (FVC) and maximal voluntary ventilation (MVV) optimal cutoff values were 87.0 (P=0.003) and 83.6 (P=0.026), respectively. Baseline characteristics of patients with low versus high FVC and MVV levels were analyzed and shown in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. We found that FVC level was associated with gender, age, body mass index (BMI), albumin, tumor size, and tumor stage (P\<0.05). MVV level was associated with age, BMI, total protein, albumin, tumor size, lymph node metastasis, and tumor stage (P\<0.05).

Our results showed that low FVC and low MVV were associated with poor prognosis in gastric cancer patients (Figure [2](#F2){ref-type="fig"} & [3](#F3){ref-type="fig"}). A univariate analysis showed that patient age, BMI, total protein, albumin, tumor size, Borrmann type, pathological type, tumor depth, lymph node metastasis, tumor stage, FVC, and MVV were associated with prognosis (Table [2](#T2){ref-type="table"}). However, only age, BMI, tumor depth, lymph node metastasis, and FVC were independent prognostic predictors (Table [3](#T3){ref-type="table"}).
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###### Univariate analysis of risk factors for prognosis of gastric cancer

  Prognostic factors      β        Hazard ratio (95% CI)   P value
  ----------------------- -------- ----------------------- ---------
  Gender                  −0.119   0.888(0.689-1.144)      0.357
  Age                     0.383    1.466(1.197-1.797)      0.000
  BMI                     −0.477   0.621(0.508-0.759)      0.000
  Total protein           −0.249   0.780(0.629-0.967)      0.023
  Albumin                 −0.297   0.743(0.592-0.932)      0.010
  Tumor location          0.023    1.023(0.923-1.134)      0.667
  Tumor size              0.822    2.275(1.857-2.787)      0.000
  Borrmann type           0.212    1.236(1.089-1.403)      0.001
  Pathological type       0.535    1.707(1.453-2.005)      0.000
  Tumor depth             0.941    2.562(2.206-2.977)      0.000
  Lymph node metastasis   0.715    2.044(1.851-2.257)      0.000
  Tumor stage             1.379    3.970(3.202-4.923)      0.000
  FVC                     −0.330   0.719(0.576-0.897)      0.003
  MVV                     −0.253   0.777(0.622-0.970)      0.026

###### Multivariate analysis of risk factors for prognosis of gastric cancer

  Prognostic factors      B        Hazard ratio (95% CI)   P value
  ----------------------- -------- ----------------------- ---------
  Age                     0.272    1.313(1.064-1.619)      0.011
  BMI                     −0.328   0.720(0.584-0.888)      0.002
  Total protein           −0.022   0.979(0.742-1.290)      0.878
  Albumin                 −0.155   0.857(0.639-1.148)      0.300
  Tumor size              0.201    1.222(0.992-1.507)      0.060
  Borrmann type           0.096    1.100(0.976-1.240)      0.118
  Pathological type       0.065    1.067(0.887-1.284)      0.494
  Tumor depth             0.594    1.811(1.488-2.204)      0.000
  Lymph node metastasis   0.481    1.618(1.445-1.811)      0.000
  FVC                     −0.296   0.743(0.590-0.937)      0.012
  MVV                     −0.097   0.908(0.719-1.146)      0.417

We then analyzed the predictive value of FVC in patients with different tumor stages. FVC was not associated with prognosis in stage I and II gastric cancer cases (Figure [4](#F4){ref-type="fig"} & [5](#F5){ref-type="fig"}). However, low FVC was associated with poor prognosis in patients with stage III gastric cancer (Figure [6](#F6){ref-type="fig"}). Univariate and multivariate analyses showed that FVC was an independent risk factor for prognosis in stage III gastric cancer patients (Tables [4](#T4){ref-type="table"} & [5](#T5){ref-type="table"}).
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###### Univariate analysis of risk factors for prognosis of stage III gastric cancer

  Prognostic factors            β        Hazard ratio (95% CI)   P value
  ----------------------------- -------- ----------------------- ---------
  Gender                        −0.031   0.969(0.734-1.280)      0.825
  Age                           0.234    1.264(1.008-1.585)      0.042
  BMI                           −0.290   0.748(0.595-0.941)      0.013
  Total protein                 −0.075   0.927(0.727-1.183)      0.544
  Albumin                       −0.168   0.846(0.653-1.096)      0.205
  Tumor location                0.100    1.105(0.989-1.234)      0.077
  Tumor size                    0.215    1.240(0.989-1.555)      0.062
  Borrmann type                 0.122    1.130(0.988-1.292)      0.074
  Pathological type             0.176    1.192(0.969-1.466)      0.096
  Tumor depth                   0.476    1.609(1.286-2.015)      0.000
  Lymph node metastasis         0.519    1.680(1.372-2.057)      0.000
  Lymphatic-vascular invasion   0.257    1.293(0.939-1.780)      0.116
  Neural invasion               0.298    1.348(0.845-2.149)      0.210
  FVC                           −0.294   0.745(0.584-0.951)      0.018
  MVV                           −0.179   0.836(0.652-1.073)      0.160

###### Multivariate analysis of risk factors for prognosis of stage III gastric cancer

  Prognostic factors      β        Hazard ratio (95% CI)   P value
  ----------------------- -------- ----------------------- ---------
  Age                     0.228    1.256(0.999-1.577)      0.051
  BMI                     −0.089   0.915(0.878-0.953)      0.000
  Tumor depth             0.625    1.869(1.489-2.346)      0.000
  Lymph node metastasis   0.614    1.848(1.509-2.262)      0.000
  FVC                     −0.362   0.696(0.543-0.893)      0.004

Finally, we analyzed relationships between FVC and MVV levels and postoperative complications (Table [6](#T6){ref-type="table"}). Low FVC and low MVV were associated with higher rates of postoperative fever (23.8% vs. 13.9%, P\<0.001; 17.8% vs. 13.3%, P=0.049, respectively). In addition, low FVC was associated with a higher rate of wound infection (1.4% vs. 0.2%, P=0.029).

###### Comparison of postoperative complications

  Complications         FVC   MVV                         
  --------------------- ----- ----- --------- ----- ----- -------
  Total cases           110   269   0.002     270   109   0.003
  Fever                 67    129   \<0.001   140   56    0.049
  Pneumonia             16    60    0.779     56    20    0.135
  Wound infection       4     2     0.029     6     0     0.098
  Wound disruption      8     8     0.017     11    5     1.000
  Anastomosis leak      4     12    0.773     11    5     1.000
  Abdominal bleeding    1     8     0.694     5     4     0.727
  Chyle leakage         1     12    0.320     8     5     0.776
  Pleural effusion      5     16    1.000     14    7     1.000
  Gastric stasis        0     3     1.000     1     2     0.280
  Ileus                 4     18    0.799     17    5     0.266
  Duodenal stump leak   0     1     1.000     1     0     1.000

DISCUSSION {#s3}
==========

Pulmonary disease is seldom clinically diagnosed unless a patient presents with overt respiratory symptoms. Thus, preoperative screening for pulmonary disease usually depends on a given patient\'s previous medical history. Preoperative screening using pulmonary function testing is likely to be more valuable than conventional assessment in terms of evaluating pulmonary abnormalities and predicting postoperative complications \[[@R7]\]. However, while preoperative pulmonary function testing is accepted as an effective tool for predicting operative risk before thoracic surgery \[[@R8]\], it is not yet routinely performed for gastric cancer patients before surgery.

Associations between preoperative pulmonary function and postoperative pulmonary complications and patient mortality have been well investigated. However, data describing the impact of pulmonary disease on radical gastrectomy outcomes were controversial. Kim, *et al*. reported that pulmonary disease was associated with postoperative morbidity in a large, multicenter, laparoscopic gastrectomy study \[[@R9]\]. Jeong, *et al*. found that preoperative pulmonary function testing effectively predicted the risk of surgical complications and systemic complications in patients undergoing gastrectomy \[[@R10]\]. However, several other studies reported that pulmonary disease did not increase the risk of postoperative complications after gastric cancer surgery \[[@R11], [@R12]\]. The present study found that low FVC and low MVV were associated with higher incidence of postoperative fever.

The prognostic value of preoperative pulmonary function has mainly been investigated in thoracic surgery \[[@R13], [@R14]\]. Guo, *et al*. reported that FVC was an independent risk factor for the prognosis of non-small cell lung cancer patients who underwent curative resection, and FVC\<80% predicted poor patient survival \[[@R13]\]. Matsuzaki, *et al*. associated low forced expiratory volume 1 (FEV1)/FVC ratios with reduced overall and disease-free survival in lung cancer patients undergoing thoracic surgery. The same group found that the carbon monoxide diffusing capacity of the lung and the inspiratory capacity/total lung capacity ratio were associated with patient prognosis \[[@R14]\]. To the best of our knowledge, no previous study has associated preoperative pulmonary function with gastric cancer patient prognosis. Our study associated low FVC and MVV with poor prognosis in gastric cancer patients, and FVC was an independent prognostic predictor.

Cachexia and weight loss in advanced gastric cancer patients were important factors predicting long-term survival. Poor respiratory function may be partly attributed to cancer-induced cachexia. Our study found that although BMI, total protein, and albumin were all associated with gastric cancer patient prognosis, FVC was the only independent risk factor for prognosis.

Multiple groups have investigated the association between FVC and survival in the general population \[[@R15]--[@R17]\]. Burnery, *et al*. reported that FVC, but not airway obstruction, predicts survival in asymptomatic adults without chronic respiratory diagnoses or persistent respiratory symptoms \[[@R16]\]. Low FVC was associated with increased mortality risk \[[@R18]\]. We suggest two possible explanations for these findings, both of which strengthen the case for using pulmonary function testing in gastric cancer patients prior to surgery. First, pulmonary function tests may reflect muscle strength and general energy levels, and physical and psychological disorders may manifest as lower values. Thus, these tests may indicate an individual patient\'s overall health. Second, poor fetal growth rates and lower birth weights may result in reduced lung function and increased risk of cardiovascular disease \[[@R19], [@R20]\]. In these cases, FVC may reflect overall cardiopulmonary function as well as general health.

There were several limitations in our present study. First, it was a retrospective analysis limited to a single center. Multi-center studies are needed to verify the predictive value of FVC. Second, our patient cohort was not large enough, and small sample sizes can result in biased statistical analyses. Third, we did not evaluate the predictive value of FVC after radical gastrectomy. Postoperative pulmonary function may play roles in gastric cancer patient prognosis, and should be explored.

Although preoperative pulmonary function has been associated with postoperative respiratory complications, the prognostic value of preoperative pulmonary function in gastric cancer patients undergoing radical surgery had not yet been investigated. In conclusion, our study demonstrated that low FVC and MVV were associated with poor prognosis and higher rates of postoperative fever in gastric cancer patients, and FVC was an independent prognostic predictor.

MATERIALS AND METHODS {#s4}
=====================

This study was performed at the Xijing Hospital of Digestive Diseases affiliated with the Fourth Military Medical University, China. From October 2008 to March 2015, a total of 1210 gastric cancer patients in our department were enrolled in the present study. Inclusion criteria were as follows: 1. without other malignant tumors, 2. without distant metastasis, 3. without neoadjuvant chemotherapy, 4. with radical D2 gastrectomy, 5. with preoperative pulmonary function test. This study was approved by the Ethics Committee of Xijing Hospital, and written informed consent was obtained from all patients before surgery.

All patients were treated with proximal, distal or total gastrectomy with D2 lymphadenectomy. The surgical procedure was based on the recommendations of the Japanese Gastric Cancer Treatment Guidelines \[[@R21]\]. Primary tumor depth and degree of lymph node involvement were defined according to the TNM classification. Postoperative chemotherapy was administrated according to the National Comprehensive Cancer Network guidelines.

Pulmonary function test was performed no more than seven days before surgery. FVC and MVV were measured by spirometry. Observed values were expressed as a percent of predicted values. Clinicopathological data, including gender, age, BMI, total protein, albumin, tumor location, tumor size, Borrmann type, type of resection, pathological type, tumor depth, lymph node metastasis and tumor stage, were collected. Postoperative complications, including fever, pneumonia, wound infection, wound disruption, anastomosis leakage, abdominal bleeding, chyle leakage, pleural effusion, gastric stasis, ileus and duodenal stump leakage, were also recorded. Patients were followed-up until November 2016, with enhanced chest and abdominal CT and gastroscopy every 3 months.

Data were processed using SPSS 22.0 for Windows (SPSS Inc., Chicago, IL, USA). Optimal FVC and MVV cutoff values for gastric cancer prognosis prediction were calculated using X-tile software \[[@R22]\]. Discrete variables were analyzed using Chi-square test or Fisher\'s exact test. Significant prognostic risk factors identified by univariate analysis were further assessed by multivariate analysis using the Cox\'s proportional hazards regression model. Overall survival was analyzed by Kaplan-Meier method. P≤0.05 was considered statistically significant.
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